We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
A few cases of carcinoids, liver, renal, ovarian, colorectal and testicular cancers along with occasional cases of gastric and pancreatic cancers displayed weak to moderate cytoplasmic and occasional nuclear staining. Remaining cancer cells were negative. Plasma was distinctly stained.
Several cases of liver cancers and a rare case of carcinoid displayed moderate cytoplasmic staining with additional membranous positivity in a few cases. Remaining cancer cells were weakly stained or generally negative.
GENE INFORMATION
Gene name
CFHR5 (HGNC Symbol)
Synonyms
CFHL5, FHR-5, FHR5
Description
Complement factor H-related 5 (HGNC Symbol)
Entrez gene summary
This gene is a member of a small complement factor H (CFH) gene cluster on chromosome 1. Each member of this gene family contains multiple short consensus repeats (SCRs) typical of regulators of complement activation. The protein encoded by this gene has nine SCRs with the first two repeats having heparin binding properties, a region within repeats 5-7 having heparin binding and C reactive protein binding properties, and the C-terminal repeats being similar to a complement component 3 b (C3b) binding domain. This protein co-localizes with C3, binds C3b in a dose-dependent manner, and is recruited to tissues damaged by C-reactive protein. Allelic variations in this gene have been associated, but not causally linked, with two different forms of kidney disease: membranoproliferative glomerulonephritis type II (MPGNII) and hemolytic uraemic syndrome (HUS). [provided by RefSeq, Jan 2010]
Q9BXR6 [Direct mapping] Complement factor H-related protein 5
Show all
Predicted secreted proteins Secreted proteins predicted by MDSEC SignalP predicted secreted proteins Phobius predicted secreted proteins SPOCTOPUS predicted secreted proteins Plasma proteins Disease related genes Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0005576 [extracellular region] GO:0006957 [complement activation, alternative pathway]
